olvimulogene nanivacirepvec
Sponsor Genelux CORP · listed as GNLX
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
olvimulogene nanivacirepvec is a clinical-stage drug asset sponsored by Genelux CORP, listed as GNLX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT05281471. The asset is in Phase 3 and currently recruiting, studied in Platinum-resistant Ovarian Cancer.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05281471
PhasePHASE3
StatusRECRUITING
Lead sponsorGenelux Corporation
Listed asGNLX
Condition(s)Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endom…
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More GNLX catalysts